Pericarditis Market Share, Industry Size, Opportunity, Analysis, Forecast 2022-2028

Comments · 59 Views

In a recent research report by Market Research Community, the pericarditis market is expected to surpass USD 5.05 Billion by the year 2030, from USD 3.2 Billion in 2021.

Pericarditis Market Overview:

Pericarditis is the inflammation of the thin- two-layered tissue sac called pericardium which holds the heart in place to help it function properly. The pericarditis cases are mild and improve on their own without the need for medical intervention. The symptoms of pericarditis are leg or abdominal swelling, cough, heart palpitations, low-grade fever, feeling sick or fatigued, shortness of breath when reclining on the back, piercing chest pain, and an overall sense of weakness.

Top Key Players of the Pericarditis Market:
Johnson Johnson Services, Inc., Novartis International AG., PerkinElmer Inc., AstraZeneca Plc., Bayer, Reckitt Benckiser, Fujifilm, Merck Sharp, and Dohme, Allergan Plc., Pfizer Inc.

Type Covered in This Report Are:

By End User:
Hospitals Clinics
Ambulatory Surgical Centers
Academic Research Institutes

On the Basis of Diagnosis:
Electrocardiogram (ECG)
Computerized Tomography (CT)

Regional Analysis:
North America–
 (U.S., Canada, Mexico)
Europe- (Germany, France, U.K., Russia, Italy, Spain, BENELUX, Rest of Europe)
Asia Pacific- (China, Japan, India, South Korea, Australia, ASEAN, Rest of Asia Pacific)
Latin America- (Brazil, Argentina, Chile, Rest of Latin America)
Middle East and Africa- (GCC, Turkey, Israel, Rest of MEA)

In a recent research report by Market Research Community, the pericarditis market is expected to surpass USD 5.05 Billion by the year 2030, from USD 3.2 Billion in 2021.

The echocardiogram is anticipated to witness substantial growth over the forecast period mainly due to the precise imaging of heart diseases using sound waves and the reduction of risks associated with cardiotoxicity.

The market is projected to grow at a significant pace reaching a CAGR of approximately 5.2%, over the forecast period of 2022–2030, despite a considerable fall in product sales during the initial phase of pandemic spread and lockdown restrictions imposed globally.

Based on region, Europe is expected to have the second largest market share in the increased growth of the pericarditis market size  in the forecast period. The factors such as the increased healthcare infrastructure development and the rising burden of rheumatoid arthritis (RA) are the major contributors to the growth of the pericarditis market in the region.


The study is consolidated into major segments and further into sub-segments, such as by type (acute, recurrent, chronic, and idiopathic), by diagnosis (electrocardiogram (ECG), echocardiogram, computerized tomography (CT), and x-ray), by treatment (medication (non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine) and surgical treatment), by end-use (hospitals clinics, ambulatory surgical centers, and academic research institutes), to forecast the market size by value; also includes the analysis of past market dynamics from 2016 – 2021, considering 2021 as the base year.                   

The research provides answers to the following key questions:

  • What is the expected growth rate of the Pericarditis Market? What will be the market size for the forecast period, 2022 - 2030?
  • What are the major driving forces responsible for transforming the trajectory of the industry?
  • Who are major vendors dominating the Pericarditis industry across different regions? What are their winning strategies to stay ahead in the competition?
  • What are the market trends business owners can rely upon in the coming years?
  • What are the threats and challenges expected to restrict the progress of the industry across different countries?
  • What are the key opportunities that business owners can bank on for the forecast period, 2022 - 2030?


Our Recently Published Reports


Market Research Community